FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv

With an innovative approach to treating heart failure, Cytokinetics touted a game-changing medicine that could someday become available for an elusive condition that effects more than 6 million in the U.S.

But that hope is flickering. In a complete response letter (CRL) to Cytokinetics on Tuesday, the FDA rejected the application for approval of heart failure candidate omecamtiv mecarbil.